Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.
Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders.
Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.
Company Details
- Employees
- 14
- Address
- 60, Avenue Rockefeller, Lyon,auvergne-Rhône-Alpes 69008,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- axoltis.com
- Keywords
- neurodegenerative diseases, neurodegeneration, spinal cord injury, peptide, neuroprotection, neural repair, regeneration, drug, biotechnology, pharma, CNS, neurology, ALS, Parkinson, Multiple Sclerosis.
- HQ
- Lyon, Auvergne-Rhône-Alpes
Axoltis Pharma Questions
Axoltis Pharma's website is axoltis.com
Axoltis Pharma's LinkedIn profile is https://fr.linkedin.com/company/axoltispharma
Axoltis Pharma has
14 employees.
View email and phone details for 14
employees at Axoltis Pharma.
Axoltis Pharma's industry is
Biotechnology Research
Axoltis Pharma's top competitors are
Bioaster,
Enyo Pharma,
Maat Pharma,
Lys Therapeutics,
Phaxiam Therapeutics,
Everzom,
Advanced Biodesign,
Arsla,
Adocia,
Stromacare.
Axoltis Pharma's categories are Biotechnology Research
